Trial details

This from Acadia

"We plan to initiate a Phase 3 randomized, double-blind,
placebo-controlled study evaluating trofinetide in 180 females with Rett
syndrome in the second half of 2019.

The Phase 3 study will be 12 weeks
long and include females with Rett syndrome 5 to 20 years of age. Half
of the study participants will receive trofinetide and half will receive
placebo.

Trofinetide has been granted Fast Track Status and Orphan Drug
Designation for Rett syndrome in the U.S. and Orphan Drug Designation
for Rett syndrome in Europe.

ACADIA has an exclusive license to develop and commercialize trofinetide in North America from Neuren Pharmaceuticals."

So whatever the corporate machinations, the trial preparations are proceeding well.
Three month trial length, targetting those under 20, where it might be expected to have more potent effect.

http://www.acadia-pharm.com/pipeline/rett-syndrome/?fbclid=IwAR1EjDaWuQwzqWuAYrvJ7iPeVp4BKdpNMwq6ehRq8iU6yY7DgF6AE4dyOy4